Cefsulodin

Jump to: navigation, search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Cefsulodin

Articles

Most recent articles on Cefsulodin

Most cited articles on Cefsulodin

Review articles on Cefsulodin

Articles on Cefsulodin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cefsulodin

Images of Cefsulodin

Photos of Cefsulodin

Podcasts & MP3s on Cefsulodin

Videos on Cefsulodin

Evidence Based Medicine

Cochrane Collaboration on Cefsulodin

Bandolier on Cefsulodin

TRIP on Cefsulodin

Clinical Trials

Ongoing Trials on Cefsulodin at Clinical Trials.gov

Trial results on Cefsulodin

Clinical Trials on Cefsulodin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cefsulodin

NICE Guidance on Cefsulodin

NHS PRODIGY Guidance

FDA on Cefsulodin

CDC on Cefsulodin

Books

Books on Cefsulodin

News

Cefsulodin in the news

Be alerted to news on Cefsulodin

News trends on Cefsulodin

Commentary

Blogs on Cefsulodin

Definitions

Definitions of Cefsulodin

Patient Resources / Community

Patient resources on Cefsulodin

Discussion groups on Cefsulodin

Patient Handouts on Cefsulodin

Directions to Hospitals Treating Cefsulodin

Risk calculators and risk factors for Cefsulodin

Healthcare Provider Resources

Symptoms of Cefsulodin

Causes & Risk Factors for Cefsulodin

Diagnostic studies for Cefsulodin

Treatment of Cefsulodin

Continuing Medical Education (CME)

CME Programs on Cefsulodin

International

Cefsulodin en Espanol

Cefsulodin en Francais

Business

Cefsulodin in the Marketplace

Patents on Cefsulodin

Experimental / Informatics

List of terms related to Cefsulodin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Overview

Cefsulodin is a third-generation cephalosporin antibiotic with specific activity against Pseudomonas aeruginosa. It has no significant activity against other Gram-negative bacteria and very limited activity against Gram-positive bacteria and anaerobic bacteria. Cefsulodin was first synthesized and patented by the Takeda Pharmaceutical Company in 1977. In 2002, Takeda stopped production of cefsulodin. Many years of low-stability cefsulodin production has led to a widespread reduction of laboratory and research uses. Current attempts (i.e. IDEXX Laboratories) of increasing purity and stability of cefsulodin center around recrystallization. Typically, the process entails: Cefsulodin is dissolved in an organic solvent, sodium ions, water, or any mixture thereof, then subsequently recrystallized through separation of the unwanted fraction. Recently, TOKU-E has found the main cause of cefsulodin instability stems from one key impurity in 7-aminocephalosporanic acid, a raw material used in the synthesis of cefsulodin. To produce high-purity, high-stability cefsulodin, TOKU-E uses industrial HPLC to remove significant quantities of this impurity in 7-ACA and thus produces ultrapure, ultrastable, and ultrapotent cefsulodin.[1]

General use

Cefuslodin is most commonly used in cefsulodin-irgasan-novobiocin agar to select for Yersinia microorganisms.[2] This agar is most often used in water and beverage testing.

Susceptibility data

The following represents MIC susceptibility data for various P. aeruginosa strains.

  • Pseudomonas aeruginosa PA13 (resistant strain): 32 μg/ml
  • Pseudomonas aeruginosa (wild-type, susceptible): 4 - 8 μg/ml

[3]

References

  1. [1], TOKU-E Technical Application Sheet.
  2. "BAM Media M35: Cefsulodin-Irgasan Novobiocin Agar or Yersinia Selective Agar". Retrieved 2 September 2012.
  3. http://antibiotics.toku-e.com/antimicrobial_474.html

Linked-in.jpg